Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Alto crecimiento
Los ingresos de la empresa han crecido de manera constante durante los últimos tres años, con un promedio interanual del 18.09%.
Infravalorada
El PE más reciente de la empresa es -10.81, en un rango percentil bajo de 3 años.
Venta institucional
Las tenencias institucionales más recientes son 71.93M acciones, lo que supone una reducción del 9.13% con respecto al trimestre anterior.
En posesión de Bill Gates
El inversor estrella Bill Gates posee 13.85M acciones de este valor.